Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Key facts
- Where
- Ajax, Bowmanville, Oshawa és Toronto, KanadaSee the 6 sites
- Phase
- 4. fázis
Where in Kanada
- Lakeridge Health Ajax-PickeringAjax, KanadaTaking people
- Lakeridge Health BowmanvilleBowmanville, KanadaTaking people
- Lakeridge Health OshawaOshawa, KanadaTaking people
- Scarborough Birchmount HospitalToronto, KanadaTaking people
- Scarborough Centenary HospitalToronto, KanadaTaking people
- Scarborough General HospitalToronto, KanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Scarborough General Hospital
- Trial code
- NCT07173855
- Record updated
- 2026. szeptember 24.
- Original description
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level.Read full original descriptionShow less
Effect of Protocolized Magnesium Replacement in Critically Ill Patients on Mortality and Atrial Fibrillation: the MAGNOLIA Randomized Controlled Trial
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level.
The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation.
Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.
Inclusion: Age 16 years or older; Admission orders written to a medical-surgical intensive care unit at a participating site; Magnesium replacement protocol ordered.
Exclusion: Prior enrollment in or withdrawal from MAGNOLIA trial; Sustained ventricular tachycardia; Pre-eclampsia; Myasthenia gravis.